Standard Biotools INC 8-K filings

Standard BioTools Inc. stockholders approved an amendment to the company's equity incentive plan, increasing the number of shares reserved for issuance by 19,125,000.

Madryn Health Partners has withdrawn its intent to nominate director candidates and submit a business proposal at Standard BioTools' upcoming 2024 annual meeting.

Standard BioTools reported first quarter 2024 financial results, exceeding expectations for cost synergies and reaffirming their full-year revenue guidance.

Standard BioTools is implementing a restructuring plan, including a 10% workforce reduction, to improve operational efficiency and reduce costs, aiming for $45-$50 million in annualized savings by 2025.

Standard BioTools Inc. has completed an exchange of all outstanding Series B Convertible Preferred Stock for approximately 93 million shares of common stock, simplifying its capital structure.

Standard BioTools achieved its 2023 financial objectives, significantly reducing expenses and cash burn while increasing revenue and gross margins, and completed its merger with SomaLogic.

Standard BioTools Inc. finalizes its acquisition of SomaLogic, Inc., with amended filings including financial statements and pro forma information.